Keros Therapeutics (KROS) Operating Leases (2019 - 2025)
Keros Therapeutics posted quarterly Operating Leases of $16.9 million for Q4 2025, little changed year-on-year from $16.9 million in Q4 2024, and up 11.73% on a QoQ basis from $15.1 million in Q3 2025.
Keros Therapeutics (KROS) has 7 years of Operating Leases data on file, last reported at $16.9 million in Q4 2025.
- For the quarter ending Q4 2025, Operating Leases changed 0.0% year-over-year to $16.9 million; the trailing twelve-month figure through Dec 2025 stood at $16.9 million (changed 0.0% YoY), and the FY2025 full-year result was $16.9 million, changed 0.0% from the prior year.
- Operating Leases for Q4 2025 stood at $16.9 million, up from $15.1 million in the prior quarter.
- Across five years, Operating Leases topped out at $17.4 million in Q3 2024 and bottomed at $231000.0 in Q4 2021.
- The 5-year median for Operating Leases is $13.4 million (2023), against an average of $10.7 million.
- The widest annual swing landed in 2021, when Operating Leases slumped 65.03%; it then surged 5484.42% in 2022.
- A 5-year view of Operating Leases shows it stood at $231000.0 in 2021, then soared by 5484.42% to $12.9 million in 2022, then increased by 4.18% to $13.4 million in 2023, then climbed by 25.63% to $16.9 million in 2024, then changed by 0.0% to $16.9 million in 2025.
- The last three Operating Leases figures came in at $16.9 million (Q4 2025), $15.1 million (Q3 2025), and $15.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.88 Mn |
| Sep 30, 2025 | 15.11 Mn |
| Jun 30, 2025 | 15.72 Mn |
| Mar 31, 2025 | 16.31 Mn |
| Dec 31, 2024 | 16.88 Mn |
| Sep 30, 2024 | 17.43 Mn |
| Jun 30, 2024 | 12.86 Mn |
| Mar 31, 2024 | 13.15 Mn |
| Dec 31, 2023 | 13.44 Mn |
| Sep 30, 2023 | 14.32 Mn |
| Jun 30, 2023 | 13.95 Mn |
| Mar 31, 2023 | 1.40 Mn |
| Dec 31, 2022 | 12.90 Mn |
| Dec 31, 2021 | 231,000.00 |
| Sep 30, 2021 | 700,000.00 |
| Jun 30, 2021 | 242,000.00 |
| Mar 31, 2021 | 361,000.00 |
| Dec 31, 2020 | 476,000.00 |
| Sep 30, 2020 | 586,000.00 |
| Jun 30, 2020 | 692,000.00 |
| Mar 31, 2020 | 797,000.00 |
| Dec 31, 2019 | 899,000.00 |